



#5 1614

TECH CENTER 1600/2900

PATENT
MAY 23 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)	Levi, et al.	Examiner:	Unassigned
Serial No.:	10/076,204	Group Art Unit:	1614
Confirmation No:	8595	Docket:	955-16
Filed:	February 13, 2002	Dated:	May 13, 2002
For:	METHOD AND COMPOSITION FOR REDUCING CARDIAC DYSFUNCTIONS WITH A SELECTIVE HISTAMINE H3 RECEPTOR AGONIST		

Commissioner for Patents
Washington, DC 20231

*I hereby certify this correspondence is being deposited
with the United States Postal Service as first class mail,
postpaid in an envelope, addressed to:
Commissioner for Patents, Washington, D.C. 20231*

on May 13, 2002

Dated: 5/13/02

Julie L. Watts

INFORMATION DISCLOSURE STATEMENT

Sir:

In order to fulfill the requirements of candor and good faith set forth in 37 C.F.R.

§1.56, Applicants submit herewith the following Information Disclosure Statement in
accordance with the provisions of 37 C.F.R. §1.97 and §1.98.

FOREIGN PATENT DOCUMENTS

<u>COUNTRY</u>	<u>PUBLICATION NO.</u>	<u>PUBLICATION DATE</u>
PCT	WO 00/20011	April 13, 2000

NON-PATENT PUBLICATIONS

1. B Malinowska, et al., "Histamine H₃ Receptors - General Characterization and Their Function in the Cardiovascular System", *Journal of Physiology and Pharmacology*, 1998. 49(2):191-211.
2. H. van der Goot, et al., "Isothiourea Analogues of Histamine as Potent Agonists or Antagonists of the Histamine H₃-Receptor" *Eur. J. Med. Chem.* 1992. 27: 511-517.
3. Iwan J.P. De Esch, et al., "Characterization of the Binding Site of the Histamine H₃ Receptor. 1. Various Approaches to the Synthesis of 2-(1H-Imidazol-4-yl) cyclopropylamine and Histaminergic Activity of (1R,2R)- and (1S,2S)-2-(1H-Imidazol-4-yl)-cyclopropylamine", *Journal of Medicinal Chemistry*, 1999. 42(7): 1115-1122.
4. Christina J. Mackins, et al., "Therapeutic Potential of H₃-receptor Agonists in Myocardial Infarction", *Exp. Opin. Invest Drugs* 2000. 9(11): 2537-2542.
5. Catherine Mazenot, et al., "Histamine H₃-receptor Stimulation is Unable to Modulate Noradrenaline Release by the Isolated Rat Heart During Ischaemia-Reperfusion", *Fundam. Clin. Pharmacol.* 1999. 13(4): 455-60.
6. Catherine Mazenot, et al., "*In vivo* Demonstration of H₃-histaminergic Inhibition of Cardiac Sympathetic Stimulation by R- α -methyl-histamine and its Prodrug BP 2.94 in the Dog", *British Journal of Pharmacology* 1999. 126: 264-268.

7. Pierre Theroux, M.D., "Myocardial Cell Protection. A Challenging Time for Action and Challenging Time of Clinical Research", *Circulation* 2000. 101:2874-2876.
8. Hans-Jurgen Rupprecht, M.D., et al., "Cardioprotective Effects of the Na^+/H^+ Exchange Inhibitor Cariporide in Patients with Acute Anterior Myocardial Infarction Undergoing Direct PTCA", *Circulation* 2000. 101:2902-2908.
9. Morris Karmazyn, et al., "The Myocardial Na^+-H^+ Exchange. Structure, Regulation and Its Role in Heart Disease", *Circulation Research* 1999. 85:777-786.
10. Eiichiro Hatta, et al., "Activation of Histamine H_3 Receptors Inhibits Carrier-Mediated Norepinephrine Release in a Human Model of Prolonged Myocardial Ischemia", *Journal of Pharmacology and Experimental Therapeutics* 1997. 283:494-500.
11. Randi B. Silver, et al., "Coupling of Histamine H_3 Receptors to Neuronal Na^+/H^+ Exchange: A Protective Mechanism in Myocardial Ischemia", *PNAS Early Edition* 2001. 1-5.
12. Rob Leurs, et al., "Therapeutic Potential of Histamine H_3 Receptor Agonists and Antagonists", *Trends in Pharmacological Sciences* 1998. 19:177-183.
13. P.K. Rangachari, "The Fate of Released Histamine: Reception, Response and Termination", *Yale Journal of Biology and Medicine* 1998. 71:173-182.

14. Randi B. Silver, et al., "Coupling of Histamine H₃ receptors to Neuronal Na⁺/H⁺ Exchange: A Novel Protective Mechanism in Myocardial Ischemia", *PNAS* 2001. 98(5):2855-2859.
15. Michiaki Imamura, et al., "Activation of Histamine H₃-Receptors Inhibits Carrier-Mediated Norepinephrine Release During Protracted Myocardial Ischemia", *Circ. Res.* 1996. 78:475-481.
16. Roberto Levi, et al., "Histamine H₃-Receptors: A New Frontier in Myocardial Ischemia", *The Journal of Pharmacology and Experimental Therapeutics* 2000. 292:825-830.
17. H.D. Holtje, et al., "Molecular Modelling Studies on Histamine H₂- and H₃- Receptor Agonists", www.pharm.uni-duesseldorf.de/forschung/mitarbeiter/sippl/Maastricht.pdf. 1-12.
18. Patrizio Blandina, "The Role of Interactions Between Histaminergic and Cholinergic Systems in Learning and Memory", www.mcmaster.ca/inabis98/huston/blandina0227/two.html.
19. Rob Leurs, et al., "Histamine Receptors", *Tocris Cookson*. www.biotrend.com/pdf/histamine.pdf. 1-6.

The above-referenced documents are listed on PTO Form 1449. We have enclosed the cited documents to facilitate reference to them.

The Examiner is respectfully requested to consider these publications in their entirety, and to indicate that he or she has done so by initializing the enclosed form PTO-1449.

Applicants are not aware of any other references to be identified at this time. If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicants' agent at the telephone number set forth below.

Respectfully submitted,



Edna I. Gergel
Registration No.: 50, 819
Agent for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
EIG:jlw

154380_1